<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>200157</ReferenceId>
        <DateLastUpdated>2020-04-27-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14592762</PubmedId>
            <Abstract>The H-2(b)-restricted CD8 T-cell response against lymphocytic choriomeningitis virus is directed against at least 10 dominant and subdominant epitopes, including two newly identified epitopes in the nucleoprotein. We have used this set of epitopes to characterize the plasticity of the hierarchy under different experimental circumstances, i.e., loss of MHC class I molecules, loss of specific epitopes (CTL escape), and prolonged antigenic stimulation (chronic infection). We found that loss of epitope-specific responses was almost inevitably associated with compensatory responses against other, subdominant, epitopes. Multiple epitope loss was required to change the hierarchy. Persistent viral infection was associated with a loss of not only the dominant response against the NP396 epitope, but also a loss of subdominant responses against nucleoprotein epitopes. In contrast, responses against glycoprotein epitopes, dominant and subdominant, survived under chronic infection conditions, and even dominated the response (GP118). Our results suggest that the fate of each specific T-cell response during chronic infection is in part determined by the origin of the cognate epitopes, i.e, the proteins from which they are processed, or, more specifically, nucleoprotein versus glycoprotein. A model in which recruitment time plays a role in the longevity of antiviral T-cell responses during persistent infection is discussed.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>93-102</ArticlePages>
            <ArticleTitle>Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>van der Most</LastName>
                    <ForeName>Robbert G</ForeName>
                </Author>
                <Author>
                    <LastName>Murali-Krishna</LastName>
                    <ForeName>Kaja</ForeName>
                </Author>
                <Author>
                    <LastName>Lanier</LastName>
                    <ForeName>J Gibson</ForeName>
                </Author>
                <Author>
                    <LastName>Wherry</LastName>
                    <ForeName>E John</ForeName>
                </Author>
                <Author>
                    <LastName>Puglielli</LastName>
                    <ForeName>Maryann T</ForeName>
                </Author>
                <Author>
                    <LastName>Blattman</LastName>
                    <ForeName>Joseph N</ForeName>
                </Author>
                <Author>
                    <LastName>Sette</LastName>
                    <ForeName>Alessandro</ForeName>
                </Author>
                <Author>
                    <LastName>Ahmed</LastName>
                    <ForeName>Rafi</ForeName>
                </Author>
            </Authors>
            <Affiliations>Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA. r.g.vandermost@vet.uu.nl.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;Glycoproteins;Immunodominant Epitopes;Nucleoproteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Acute Disease; Amino Acid Sequence; Animals; Antigen Presentation; CD8-Positive T-Lymphocytes(immunology); Chronic Disease; Disease Models, Animal; Epitopes, T-Lymphocyte(immunology); Glycoproteins(immunology); Immunodominant Epitopes(immunology); Immunologic Memory; Lymphocytic Choriomeningitis(immunology); Lymphocytic choriomeningitis virus(immunology); Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nucleoproteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>315</Volume>
                <Issue>1</Issue>
                <Title>Virology</Title>
                <Issn>1096-0341</Issn>
                <MedlineTa>Virology</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>GP34-43</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVYNFATCGI</LinearSequence>
                        <StartingPosition>34</StartingPosition>
                        <EndingPosition>43</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>5627</EpitopeId>
                <ReferenceStartingPosition>34</ReferenceStartingPosition>
                <ReferenceEndingPosition>43</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269504</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant, which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP33-43</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYNFATCGI</LinearSequence>
                                        <StartingPosition>34</StartingPosition>
                                        <EndingPosition>43</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. GP33 stimulates both the D&lt;sup&gt;b&lt;/sup&gt;-restricted GP33 and K&lt;sup&gt;b&lt;/sup&gt;-restricted GP34 responses. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt;GP276 at day 68 postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3b and 6</LocationOfData>
                        <TCellId>1269631</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 1 dose i.p. of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU starin Armstrong or 1 dose i.v. of 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP34-43</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AVYNFATCGI</LinearSequence>
                                        <StartingPosition>34</StartingPosition>
                                        <EndingPosition>43</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD8 T cells in LCMV-infected mice were identified by MHC class I tetramer staining. At day 8 postinfection with strain Armstrong, the hierarchy of epitope response was NP396 ≥ GP33 &gt; GP34 &gt; NP205 &gt; GP276. Strain A22.2b, which generates a chronic infection, elicits an overall weaker response and alters the hierarchy at day 8 such that GP33 ≥ NP205 &gt; NP396 &gt; GP34 &gt; GP276. By day 68 postinfection with strain A22.2b, the NP responses are lost and the hierarchy is GP33 &gt; GP34 ≥ GP276 &gt; &gt; NP205 &gt; NP396. K&lt;sup&gt;b&lt;/sup&gt; restriction of GP34 was shown by a negative response in H-2K&lt;sup&gt;b&lt;/sup&gt; knockout mice and a positive response in H-2D&lt;sup&gt;b&lt;/sup&gt; knockouts 8 days postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP92-101</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSANNSHHYI</LinearSequence>
                        <StartingPosition>92</StartingPosition>
                        <EndingPosition>101</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>6972</EpitopeId>
                <ReferenceStartingPosition>92</ReferenceStartingPosition>
                <ReferenceEndingPosition>101</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269705</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV strain Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant, which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP92-101</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSANNSHHYI</LinearSequence>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. The GP92 response is barely detectable in WT mice after acute infection with strain Armstrong or chronic infection with strain A22.2b and its L1 variant, which carries a mutation in GP33. The GP92 response becomes codominant with epitopes GP276 and NP163 in H-2K&lt;sup&gt;b&lt;/sup&gt; knockout mice at day 68 postinfection with strain A22.2b L1 variant in which the GP33 response is removed by the L1 viral mutation, the K&lt;sup&gt;b&lt;/sup&gt;-restricted GP118 and GP34 responses are prevented by the knockout, and most NP-specific responses are negligible after chronic infection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP396-404</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FQPQNGQFI</LinearSequence>
                        <StartingPosition>396</StartingPosition>
                        <EndingPosition>404</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>17516</EpitopeId>
                <ReferenceStartingPosition>396</ReferenceStartingPosition>
                <ReferenceEndingPosition>404</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269468</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV strain Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP396-404</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FQPQNGQFI</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>404</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt; GP276 at day 68 postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>1269620</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 1 dose i.p. of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong or 1 dose i.v. of 10&lt;sup&gt;6&lt;/sup&gt; PFU LCMV A22.2b.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP396-404</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FQPQNGQFI</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>404</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD8 T cells in LCMV-infected mice were identified by MHC class I tetramer staining. At day 8 postinfection with strain Armstrong, the hierarchy of epitope response was NP396 ≥ GP33 &gt; GP34 &gt; NP205 &gt; GP276. Strain A22.2b, which generates a chronic infection, elicits an overall weaker response and alters the hierarchy at day 8 such that GP33 ≥ NP205 &gt; NP396 &gt; GP34 &gt; GP276. By day 68 postinfection with strain A22.2b, the NP responses are lost and the hierarchy is GP33 &gt; GP34 ≥ GP276 &gt; &gt; NP205 &gt; NP396.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP235-249</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>INISGYNFSLGAAVK</LinearSequence>
                        <StartingPosition>235</StartingPosition>
                        <EndingPosition>249</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>27664</EpitopeId>
                <ReferenceStartingPosition>235</ReferenceStartingPosition>
                <ReferenceEndingPosition>249</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Epitope was identified using overlapping 15-mer peptides spanning NP.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269478</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected  i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP235-249</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>INISGYNFSLGAAVK</LinearSequence>
                                        <StartingPosition>235</StartingPosition>
                                        <EndingPosition>249</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt; GP276 at day 68 postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP118-125</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ISHNFCNL</LinearSequence>
                        <StartingPosition>118</StartingPosition>
                        <EndingPosition>125</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>28528</EpitopeId>
                <ReferenceStartingPosition>118</ReferenceStartingPosition>
                <ReferenceEndingPosition>125</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269479</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 1 dose i.p. of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU  strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or  A22.2b-L1 variant which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP118-125</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ISHNFCNL</LinearSequence>
                                        <StartingPosition>118</StartingPosition>
                                        <EndingPosition>125</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt; GP276 at day 68 postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP33-43</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATCGI</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>43</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>30005</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>43</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269480</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant, which carries a V to A mutation at position 35 in G.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP33-43</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATCGI</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>43</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. GP33 stimulates both the D&lt;sup&gt;b&lt;/sup&gt;-restricted GP33 and K&lt;sup&gt;b&lt;/sup&gt;-restricted GP34 responses. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt;GP276 at day 68 postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3b and 6</LocationOfData>
                        <TCellId>1269632</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 1 dose i.p. of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU strain Armstrong or 1 dose i.v. of 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP33-43</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATCGI</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>43</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD8 T cells in LCMV-infected mice were identified by MHC class I tetramer staining. At day 8 postinfection with strain Armstrong, the hierarchy of epitope response was NP396 ≥ GP33 &gt; GP34 &gt; NP205 &gt; GP276. Strain A22.2b, which generates a chronic infection, elicits an overall weaker response and alters the hierarchy at day 8 such that GP33 ≥ NP205 &gt; NP396 &gt; GP34 &gt; GP276. By day 68 postinfection with strain A22.2b, the NP responses are lost and the hierarchy is GP33 &gt; GP34 ≥ GP276 &gt; &gt; NP205 &gt; NP396. D&lt;sup&gt;b&lt;/sup&gt; restriction of GP33 is shown by a negative response on H-2D&lt;sup&gt;b&lt;/sup&gt; knockout mice and a positive response on H-2K&lt;sup&gt;b&lt;/sup&gt; knockouts 8 days postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP163-177</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KDSSLLNNQFGTMPS</LinearSequence>
                        <StartingPosition>163</StartingPosition>
                        <EndingPosition>177</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>30254</EpitopeId>
                <ReferenceStartingPosition>163</ReferenceStartingPosition>
                <ReferenceEndingPosition>177</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Epitope was identified using overlapping 15-mer peptides spanning NP.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269500</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected  i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP163-177</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KDSSLLNNQFGTMPS</LinearSequence>
                                        <StartingPosition>163</StartingPosition>
                                        <EndingPosition>177</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. The NP163 response is weakly detected in WT mice after acute infection with strain Armstrong or chronic infection with strain A22.2b and its L1 variant, which carries a mutation in GP33. The NP163 response is greater in H-2K&lt;sup&gt;b&lt;/sup&gt; knockout mice which do not respond to the more dominant GP34, GP118, NP205, and NP235 epitopes. The NP163 response becomes codominant with epitopes GP276 and GP92 in H-2K&lt;sup&gt;b&lt;/sup&gt; knockout mice at day 68 postinfection with strain A22.2b L1 variant in which the GP33 response is removed by the L1 viral mutation, the GP118 and GP34 responses are prevented by the knockout, and most NP-specific responses are negligible after chronic infection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP276-286</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                        <StartingPosition>276</StartingPosition>
                        <EndingPosition>286</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>58282</EpitopeId>
                <ReferenceStartingPosition>276</ReferenceStartingPosition>
                <ReferenceEndingPosition>286</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269482</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant , which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP276-286</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>286</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt; GP276 at day 68 postinfection with strain A22.2b, and GP276 &gt; GP92 &gt; NP163 at day 68 postinfection with strain A22.2b L1 variant.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>1269633</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 1 dose i.p. of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU strain Armstrong or 1 dose i.v. of 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP276-286</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>286</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD8 T cells in LCMV-infected mice were identified by MHC class I tetramer staining. At day 8 postinfection with strain Armstrong, the hierarchy of epitope response was NP396 ≥ GP33 &gt; GP34 &gt; NP205 &gt; GP276. Strain A22.2b, which generates a chronic infection, elicits an overall weaker response and alters the hierarchy at day 8 such that GP33 ≥ NP205 &gt; NP396 &gt; GP34 &gt; GP276. By day 68 postinfection with strain A22.2b, the NP responses are lost and the hierarchy is GP33 &gt; GP34 ≥ GP276 &gt; &gt; NP205 &gt; NP396.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP205-212</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YTVKYPNL</LinearSequence>
                        <StartingPosition>205</StartingPosition>
                        <EndingPosition>212</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09992.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 1</LocationOfData>
                <EpitopeId>76205</EpitopeId>
                <ReferenceStartingPosition>205</ReferenceStartingPosition>
                <ReferenceEndingPosition>212</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2, 3, 4, and 5</LocationOfData>
                        <TCellId>1269483</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU strain Armstrong. To establish a chronic infection mice were injected i.v. with 10&lt;sup&gt;6&lt;/sup&gt; PFU strain A22.2b or A22.2b-L1 variant, which carries a V to A mutation at position 35 in GP33.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP205-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YTVKYPNL</LinearSequence>
                                        <StartingPosition>205</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CD8+ T cells from LCMV-immunized mice produce IFN-γ in response to epitope. At day 8 and 68 after acute infection with strain Armstrong, the response is dominated by epitopes NP396 and GP33/34 with weaker responses to GP276, GP118, NP205, and NP235, and negligible responses to GP92 and NP163. Infection with strain A22.2b, which establishes a chronic infection, reduces the overall response magnitude but increases the dominance of weak epitopes, such that the response hierarchy is NP396 &gt; GP33/34 &gt; GP118 &gt; NP205 &gt; GP276 &gt; NP235 at day 8. By day 68, NP-specific responses are negligible and the response is dominated by GP33/34, GP118 and GP276. Infection with strain A22.2b-L1 variant, which carries a mutation at residue 35 in GP33, eliminates the GP33 response and reduces the GP34 response. In H-2D&lt;sup&gt;b&lt;/sup&gt; knockout (KO) mice, NP396, GP33, GP276, GP92, and NP163 responses are eliminated and the response is dominated by GP34, GP118, NP205, and NP235 at day 8 and by GP34 and GP118 at day 68 postinfection with strain A22.2b or L1. The GP34, GP118, NP205, and NP235 responses are eliminated in H-2K&lt;sup&gt;b&lt;/sup&gt; KO mice resulting in a hierarchy of NP396 &gt; GP33 at day 8 and GP33 &gt; GP276 at day 68 postinfection with strain A22.2b.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>1269634</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus (strain Armstrong)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 1 dose i.p. of 2 x 10&lt;sup&gt;5&lt;/sup&gt; PFU LCMV Armstrong or 1 dose i.v. of 10&lt;sup&gt;6&lt;/sup&gt; PFU LCMV A22.2b.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP205-212</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YTVKYPNL</LinearSequence>
                                        <StartingPosition>205</StartingPosition>
                                        <EndingPosition>212</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09992.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD8 T cells in LCMV-infected mice were identified by MHC class I tetramer staining. At day 8 postinfection with strain Armstrong, the hierarchy of epitope response was NP396 ≥ GP33 &gt; GP34 &gt; NP205 &gt; GP276. Strain A22.2b, which generates a chronic infection, elicits an overall weaker response and alters the hierarchy at day 8 such that GP33 ≥ NP205 &gt; NP396 &gt; GP34 &gt; GP276. By day 68 postinfection with strain A22.2b, the NP responses are lost and the hierarchy is GP33 &gt; GP34 ≥ GP276 &gt; &gt; NP205 &gt; NP396.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

